TCL Archive Phase III Trial of Imbruvica Halted, Following Increases in Progression-Free Survival January 31, 2014
TCL Archive NCI Board of Scientific Advisors rejects the Institute’s $89 million proteomics research plan. March 11, 2005
TCL Archive In Brief: NCHSR Says Autologous Marrow Transplant Is A “Reasonable Therapeutic Alternative” August 11, 1989